Suppliers / Zhejiang Haisen Pharmaceutical

Zhejiang Haisen Pharmaceutical

China 5 employees Updated 9 July 2026

Zhejiang Haisen Pharmaceutical is an API manufacturer based in China. It holds 4 active US drug master files and 4 valid CEPs across a filed portfolio of 5 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 15 November 2024 as VAI.

4
active US DMFs
4
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 15 November 2024 VAI US FDA
  • 12 December 2014 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Xiangtan Village, China Not on file
China, China 3003967524

What they file, and where

Molecule Regulators Docs
Atorvastatin EDQM, US FDA 3
Sucralfate EDQM, US FDA 2
Escitalopram US FDA 1
Metamizole EDQM 1
Paroxetine US FDA 1

Also appears on these molecule pages

Atorvastatin API Paroxetine API Sucralfate API Escitalopram API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Haisen Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 15 November 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates